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Deciphering the interplay between cysteine
synthase and thiol cascade proteins in the
survival of L. donovani under oxidative stress
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Background: Leishmania possess a unique trypanothione-
dependent redox metabolism with pivotal role in protection from
oxidative damage and drug resistance. The cascade of trypanoth-
ione biosynthesis depends on L-cysteine as the precursor, whereas,
cysteine bioavailability is itself dependent on the cysteine biosyn-
thesis pathway which includes enzyme cysteine synthase (CS).
However, despite the apparent dependency of redox metabolism
on cysteine biosynthesis pathway, the role of CS in drug resistance
and redox homeostasis has remained unexplored. Herein, we have
attempted to investigate the role of LdCS in Amphotericin B (Amp
B) sensitive vs. resistant isolates of L. donovani.
Methods & Materials: LdCS was cloned in pXG-GFP+ vector to
express LdCS as fusion proteins with a C-terminal GFP tag. The
construct LdCS-GFP was transfected by electroporation in the L.
donovani sensitive strainpromastigotes and transformants selected
upto ﬁnal concentration of 200 g/ml G418. MTT assay was per-
formed to determine IC50 value of LdCS-GFP overexpressor and
Amp B sensitive strains of L. donovani under different ROS induc-
ers such as, H2O2, menadione and SNAP. Further, ROS levels, thiol
content and enzymatic activities of LdCS, peroxidase and SODwere
analyzed.
Results: Our results demonstrate stage-speciﬁc increase of LdCS
expression and its enzymatic activity, accompanied by a higher
thiol content, which implies that LdCS is upregulated in Amp B
resistant isolates and during stationary stages of growth to meet
the increased thiol demand of respective stages/isolates culmi-
nating into enhanced stress tolerance. In fact, overexpression of
LdCS-GFP in sensitive strains imparted enhanced oxidative stress
tolerance to the over-expressing parasites as compared to the wild
type (WT) parasites. The IC50 values of LdCS-GFP toward H2O2,
menadione and SNAP was found to be 217±8.7M, 16.5±2.5M
and 370±9.7M, respectively, which was ∼1.87, ∼2.21 and ∼1.34
fold higher than WT parasites. Furthermore, enzymatic assays,
thiol content and immunoblot analysis showed that these oxidants
induced LdCS-GFP, as well as endogenous CS and thiol cascade
proteins expression in L. donovani suggesting a ROS regulated
mechanism of LdCS expression and thiol pathway proteins.
Conclusion: The LdCS expression is modulated by ROS proba-
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Background: Visceral Leishmaniasis (VL) is a major public
health problem in the Indian subcontinent.Mononuclear cells have
direct role in initiation of inﬂammation, anti parasitic defences and
ultimately in maintenance of tissue homeostasis. Monocytes play
an important role as immune effector cells but their role in VL is not
well known.Wehypothesised thatM2macrophagesplay an impor-
tant role in VL pathogenesis and aimed to characterise monocytes
phenotypically and functionally.
Methods & Materials: We established M1 and M2 macrophage
polarization dynamics in the whole blood of active VL patients
at an intervals of 7 days for four weeks until their drug treat-
mentwas complete.Monocyteswere phenotypically charecterised
by immunophenotyping studies for chemokine receptors CCR2,
CX3CR1, CCR7 and cell adhesion molecules VCAM1, ICAM1,
PECAM1. Functional charecterization includes quantitation of
intracellular TNF-, IL-6, IL-1 production, gene expression level
measurement of various M1, M2 markers in CD14 enriched cells
from active and cured VL cases and in endemic healthy controls.
Myeloperoxidase expression, phagocytosis and intracellular Leish-
mania parasite killing by monocytes were also examined.
Results: We found only minor changes in the frequency of
M1 and M2 macrophages at the beginning and end of drug treat-
ment, but observed several signiﬁcant changes in the expression
of cell surface markers (CD206, CD163) used to identify these cell
subsets. In particular, we found that M2 macrophages increased
in frequency and changed expression of cell surface molecules
14 days after drug treatment commenced, suggesting a potential
role in tissue repair and homeostasis. We also observed signiﬁ-
cantly upregulated expression of several M2 markers (TGM2, PKM,
SLC2A1) at gene level. We found reduced expression of CD14 on
monocytes fromactiveVLpatients, but exacerbatedTNF-, IL-6 and
dercreased production of IL-1 in response to SLA/LPS stimulation,
comparedwith the samecells fromdrug cured andendemic control
samples. We also found decreased myeloperoxidase expression by
monocytes in VL.
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Conclusion: Together, our ﬁndings indicate dynamic changes
to macrophage and monocytes populations in VL patients over the
course of drug treatment, and suggest that the functions of these
cells may change at different stages of disease. We found upregu-
lation of some markers for monocyte deactivation.
http://dx.doi.org/10.1016/j.ijid.2016.02.815
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Microplate whole blood interferon- release
assay for marker of Leishmania donovani
infection
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Background: Laboratory tests which can be produced in a
reproducible and scalable manner are much needed to identify
visceral leishmaniasis (VL) infection and fulﬁll the goals of the elim-
ination campaign. Whole blood interferon gamma (IFN-) release
assay (IGRAs) is an in vitro immune test that has recently been
developed as an alternative to the Leishmanin skin test (LST) for
identiﬁcation of individuals exposed to L.donovani infection but
without disease. Requirement of 3 ml of blood preclude this test
widely acceptable for larger community based studies. This study
aimed at evaluating the performance of microplate based IGRA
using 300l blood (direct blood as well as 1:1RPMI diluted blood)
with conventional IGRA (3ml blood) to establish this assay as an
epidemiological tool for marker of infection.
Methods & Materials: We employed conventional IGRA and
microplate based IGRA with direct as well as diluted venous blood
using soluble leishmania antigen (SLA) on patients with active vis-
ceral leishmaniasis (VL, n =32), patients with cured VL (n=20),
endemic Healthy Controls (EHC, n =21) and healthy control sub-
jects living in non-endemic area (NEHC, n=12). IFN levels in
culture supernatants were measured by ELISA and kappa statistics
was used to access the concordance between test assay formats.
Results: The whole blood cells of both active VL and cured
VL produced signiﬁcantly level of IFN- in both format of IGRA.
Positive correlations were found with active VL blood in IFN- pro-
ductionbetween3mlvs600l, 3mlvs300l, and600l vs 300l,
whilewith curedVLblood itwasmoderatewith3ml vs 600l; 3ml
vs 300l. No signiﬁcant difference in the overall IFN- response by
both assay formatswasdetected, and agreement between testswas
signiﬁcant.
Conclusion: We demonstrate a reliable and scalable process
similar in sensitivity to conventional IGRA, but with the advantage
of 10 times less venous blood requirement and higher through-put.
Development of microplate based IGRA format will be useful tool
for providing the means to more efﬁcient screening in large scale
immunological and epidemiological studies and ﬁll an unmet need
in the VL elimination campaign on the Indian sub-continent.
http://dx.doi.org/10.1016/j.ijid.2016.02.816
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Decreased miltefosine susceptibility in clinical
isolates of Leishmania donovani derived from
visceral leishmaniasis and post kala-azar
dermal leishmaniasis: Apparent mechanisms
and clinical implications
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Background:Miltefosine is an oral antileishmanial drug. Recent
reports indicate a signiﬁcant decline in its efﬁcacy and high relapse
rate in visceral leishmaniasis (VL) and post kala-azar dermal leish-
maniasis (PKDL). Miltefosine susceptibility of relapse case isolates
were >3 fold lower compared to pre treatment isolates.
Methods & Materials: To understand mechanism responsible
for miltefosine unresponsiveness, we determined (i) the sequence
of LdMTandLdRosgenes implicated inmiltefosine translocation (ii)
miltefosine accumulation and reactive oxygen species (ROS) toler-
ance and (iii) transcriptomeproﬁle in clinical isolates of Leishmania
donovani obtained from VL and PKDL patient at pre treatment
and clinically relapsed stages as well as miltefosine resistant para-
site(LdM30).
Results: LdMT gene sequencing revealed the previously
reported single-nucleotide polymorphism, C1259→A resulting in
substitution of Thr 420→Asn and a novel SNP T527-A result-
ing in substitution of Val176-Asp resistant parasites. L. donovani
parasites from VL and PKDL patients relapsed after miltefosine
treatment exhibited signiﬁcantly lower accumulation of miltefo-
sine compared with wild type parasites. Miltefosine induced ROS
levels were signiﬁcantly low (p<0.05) in macrophages infected
with LdM30 and parasites from relapse cases compared to wild
type parasites, indicating better tolerance for oxidative stress in
unresponsive clinical isolates. Transcriptome proﬁling revealed
that several genes involved in antioxidant defense mechanism
(TRYP, Cyt b5 Red, TSH),metabolic process (Lipase precursor, PGM-
PUT), transporters (VPTM,MDRP), cell component and cell motility
(SMP2, NUP155, CYP) are preferentially expressed in LdM30 and
relapsedcaseparasites thanwild typeL. donovaniparasites. Several
othergenesmainly transporters likeABCF2, aminoacid transporter,
surface acylated putative protein, APH and mitochondrial precur-
sor peptide, chaperon TCP20, clathrin coated assembly protein,
C5 sterol desaturase, autophagy protein ATG10 were preferen-
tially expressed in wild type parasite compared to relapse case and
LdM30 parasites.
Conclusion: The present study provides the understanding of
parasitic factors and pathways responsible for miltefosine unre-
sponsiveness in VL and PKDL. Decreased miltefosine susceptibility
and increasing relapse rate in VL and PKDL patients indicate the
declining efﬁcacy of monotherapy with miltefosine and warrants
the need of introducing alternate drugs/ combination therapy with
miltefosine.
http://dx.doi.org/10.1016/j.ijid.2016.02.817
